Bradley Foster & Sargent Inc. CT reduced its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 2.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 203,362 shares of the medical research company’s stock after selling 4,294 shares during the period. Thermo Fisher Scientific accounts for 1.5% of Bradley Foster & Sargent Inc. CT’s investment portfolio, making the stock its 16th biggest holding. Bradley Foster & Sargent Inc. CT owned 50,813.82% of Thermo Fisher Scientific worth $38,476,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Covington Capital Management lifted its stake in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. Covington Capital Management now owns 2,144 shares of the medical research company’s stock valued at $374,000 after purchasing an additional 20 shares during the last quarter. Investment Centers of America Inc. lifted its stake in shares of Thermo Fisher Scientific by 1.6% in the 2nd quarter. Investment Centers of America Inc. now owns 1,317 shares of the medical research company’s stock valued at $230,000 after purchasing an additional 21 shares during the last quarter. Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Thermo Fisher Scientific by 0.4% in the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 6,250 shares of the medical research company’s stock valued at $1,090,000 after purchasing an additional 23 shares during the last quarter. Azimuth Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 0.8% in the 1st quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock valued at $493,000 after purchasing an additional 25 shares during the last quarter. Finally, Bienville Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 1.6% in the 2nd quarter. Bienville Capital Management LLC now owns 1,687 shares of the medical research company’s stock valued at $295,000 after purchasing an additional 27 shares during the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

In other news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now owns 252,577 shares in the company, valued at approximately $47,582,981.03. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the transaction, the vice president now owns 19,751 shares in the company, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. 0.49% of the stock is owned by insiders.

Thermo Fisher Scientific Inc (NYSE TMO) traded down $3.68 during trading on Thursday, reaching $192.62. 2,182,900 shares of the company’s stock were exchanged, compared to its average volume of 1,542,023. The firm has a market cap of $78,715.40, a price-to-earnings ratio of 21.57, a price-to-earnings-growth ratio of 1.80 and a beta of 1.08. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business’s revenue was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.03 EPS. analysts forecast that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.19%.

Several equities research analysts recently issued reports on TMO shares. Cowen reaffirmed an “outperform” rating and issued a $220.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Leerink Swann lifted their price objective on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, October 9th. Deutsche Bank set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, October 26th. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Goldman Sachs Group started coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective for the company. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $205.71.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/30/thermo-fisher-scientific-inc-tmo-shares-sold-by-bradley-foster-sargent-inc-ct.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.